The price of Century Therapeutics Inc. (NASDAQ:IPSC) shares last traded on Wall Street rose 2.43% to $4.64.
Based on available information, 10 analysts follow Century Therapeutics Inc. (NASDAQ:IPSC). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $28.00 and a low of $14.00, we find $19.00. Given the previous closing price of $4.53, this indicates a potential upside of 319.43 percent. IPSC stock price is now -40.13% away from the 50-day moving average and -51.32% away from the 200-day moving average. The market capitalization of the company currently stands at $267.12M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Among analysts, 1 rate the stock a hold while 9 rate it a buy. Brokers who have rated the stock have averaged $19.44 as their price target over the next twelve months.
With the price target of $19, Chardan Capital Markets recently initiated with Buy rating for Century Therapeutics Inc. (NASDAQ: IPSC). On October 31, 2022, Guggenheim recently initiated its ‘Buy’ rating on the stock quoting a target price of $15, while ‘Canaccord Genuity’ rates the stock as ‘Buy’.
In other news, Versant Venture Capital VI, L., 10% Owner sold 550,000 shares of the company’s stock on Aug 09. The stock was sold for $7,166,610 at an average price of $13.03. Upon completion of the transaction, the 10% Owner now directly owns 11,816,814 shares in the company, valued at $54.83 million. Insiders disposed of 1,093,796 shares of company stock worth roughly $5.08 million over the past 1 year. A total of 36.54% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IPSC stock. A new stake in Century Therapeutics Inc. shares was purchased by BAKER BROS. ADVISORS LP during the first quarter worth $1,720,000. KETTLE HILL CAPITAL MANAGEMENT, LLC invested $251,000 in shares of IPSC during the first quarter. In the first quarter, DIMENSIONAL FUND ADVISORS LP acquired a new stake in Century Therapeutics Inc. valued at approximately $174,000. TREXQUANT INVESTMENT LP acquired a new stake in IPSC for approximately $114,000. WALLEYE TRADING LLC purchased a new stake in IPSC valued at around $57,000 in the second quarter. In total, there are 100 active investors with 58.30% ownership of the company’s stock.
A candlestick chart of Century Therapeutics Inc. (NASDAQ: IPSC) showed a price of $4.5100 on Tuesday morning. During the past 12 months, Century Therapeutics Inc. has had a low of $4.34 and a high of $15.38. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 13.40, and a quick ratio of 13.40. The fifty day moving average price for IPSC is $7.7502 and a two-hundred day moving average price translates $9.5316 for the stock.
The latest earnings results from Century Therapeutics Inc. (NASDAQ: IPSC) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.54, missing analysts’ expectations of -$0.52 by -0.02. This compares to -$0.48 EPS in the same period last year. For the current quarter, analysts expect IPSC to generate $1.09M in revenue.
Century Therapeutics Inc.(IPSC) Company Profile
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company’s lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
